Scarica l'app Stockscreener
251.34
3.00%
7.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$244.11
Aprire:
$244.75
Volume 24 ore:
2.25M
Relative Volume:
0.33
Capitalizzazione di mercato:
$443.91B
Reddito:
$62.82B
Utile/perdita netta:
$3.60B
Rapporto P/E:
123.97
EPS:
2.0274
Flusso di cassa netto:
$19.98B
1 W Prestazione:
+0.61%
1M Prestazione:
+13.02%
6M Prestazione:
+17.31%
1 anno Prestazione:
+31.94%
Intervallo 1D:
$243.50
$252.82
Intervallo di 1 settimana:
$243.07
$252.82
Portata 52W:
$184.63
$261.63
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
251.25 | 431.29B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,170.07 | 1.03T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
248.59 | 594.63B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
127.89 | 305.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.32 | 287.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
Is AbbVie (NYSE:ABBV) Fully Valued After Tepkinly? - Kalkine Media
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send? - TradingKey
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF - The Motley Fool
Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow? - simplywall.st
AHA urges court to reject AbbVie bid to change 340B program rules - EIN News
AbbVie stock holds steady as its diversified portfolio underpins long-term growth - Ad Hoc News
ABBV Maintained by Citigroup -- Price Target Raised to $260 - GuruFocus
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? - TradingView
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap - Yahoo Finance
Nxera Pharma Webinar for Financial Results Presentation - GlobeNewswire Inc.
Red day on Tuesday for AbbVie stock after losing 1.31% - StockInvest.us
AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run - Yahoo Finance
AbbVie Tokenized Stock price today, ABBVX to USD chart, marketcap and volume - CryptoSlate
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (ABBV) Faces Seventh Consecutive Loss Amid Mixed Sentimen - GuruFocus
AbbVie extends slide to a seventh straight session - MSN
AbbVie price seeks a supportive bottomForecast today14-07-2026 - Economies.com
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo! Finance Canada
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development - Investing News Network
AbbVie stock: Is ABBV outperforming the healthcare sector? - MSN
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
AbbVie pharmaceutical project moves forward in Durham: 'Huge deal' - ABC11 News
Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal - Stock Titan
ABBV Maintained by UBS -- Price Target Raised to $260 - GuruFocus
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating - marketscreener.com
ABBV Maintained by BMO Capital -- Price Target Raised to $300 - GuruFocus
UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating - marketscreener.com
Why is AbbVie stock climbing today? By Investing.com - Investing.com Canada
BMO raises Abbvie stock price target to $300 on Skyrizi strength - Investing.com
AbbVie stock holds steady on its antibody and immunology franchise - ad-hoc-news.de
AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities - PR Newswire
AbbVie stock holds steady after a new U.S. market backdrop - ad-hoc-news.de
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY) - The Globe and Mail
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $276 - Moomoo
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Sco - GuruFocus
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business - Yahoo Finance
ABBV Maintained by B of A Securities -- Price Target Raised to $276 - GuruFocus
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner - AOL.com
AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside - TradingView
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands - Investorideas.com
ABBV Maintains Overweight Rating -- Price Target Raised to $295 - GuruFocus
BofA Securities Adjusts AbbVie Price Target to $276 From $234 - marketscreener.com
ABBV Maintained by RBC Capital -- Price Target Raises to $260 - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $276 to $295 - Moomoo
AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says - marketscreener.com
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating - marketscreener.com
Wells Fargo Adjusts Price Target on AbbVie to $295 From $260 - marketscreener.com
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):